This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04842032
Recruitment Status : Active, not recruiting
First Posted : April 12, 2021
Last Update Posted : April 11, 2023
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin Co., Ltd.

Brief Summary:
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH

Condition or disease Intervention/treatment Phase
X-linked Hypophosphatemia (XLH) Drug: KRN23 Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)
Actual Study Start Date : November 1, 2021
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Experimental: KRN23
KRN23 0.8 mg/kg starting dose, administered Q2W by SC injection up to Week 64. Before KRN23 treatment, all patients will receive oral phosphate and vitamin D analogs for 12 weeks of Run-in period.
Drug: KRN23
KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
Other Names:
  • Burosumab
  • Crysvita




Primary Outcome Measures :
  1. Change from Baseline (CFB) in mean serum phosphorus level at the end of the dose cycle [ Time Frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 52, and 64 ]

Secondary Outcome Measures :
  1. Change in rickets at Weeks 40 and 64 as examined by the Radiograph Global Impression of Change (RGI-C) global score [ Time Frame: Weeks 40 and 64 ]
    Changes in the severity of rickets and bowing were assessed using a disease specific qualitative RGI-C scoring system. The RGI-C is a 7-point ordinal scale with possible values: +3 = very much better (complete or near complete healing of rickets), +2 = much better (substantial healing of rickets), +1 = minimally better (i.e., minimal healing of rickets), 0 = unchanged, -1 = minimally worse (minimal worsening of rickets), -2 = much worse (moderate worsening of rickets), -3 = very much worse (severe worsening of rickets).

  2. Change in Rickets Severity Score (RSS) total score at Weeks 40 and 64 [ Time Frame: Weeks 40 and 64 ]
    The RSS system is a 10-point radiographic scoring method that was developed to assess the severity of nutritional rickets in the wrists and knees based on the degree of metaphyseal fraying, cupping, lucency, separation, and the proportion of the growth plate affected. Scores are assigned for the unilateral wrist and knee X-rays deemed by the rater to be the more severe of the bilateral images. The maximum total score on the RSS is 10 points and the minimum score is 0, with a total possible score of 4 points for the wrists and 6 points for the knees (the total score is the sum of the wrist and knee score). Higher scores indicate greater rickets severity.

  3. Change in lower extremity skeletal abnormalities, including genu varum and genu valgus, as determined by the RGI-C long leg score at Weeks 40 and 64 [ Time Frame: Weeks 40 and 64 ]
    Changes in the severity of lower extremity skeletal abnormalities, including genu varum and genu valgus, were assessed using a disease specific qualitative RGI-C scoring system. The RGI-C is a 7-point ordinal scale with possible values: +3 = very much better (complete or near complete healing), +2 = much better (substantial healing), +1 = minimally better (i.e., minimal healing), 0 = unchanged, -1 = minimally worse (minimal worsening), -2 = much worse (moderate worsening), -3 = very much worse (severe worsening).

  4. Change in serum phosphorus over time [ Time Frame: Weeks 0, 1, 2, 4, 8, 12, 16, 24, 32, 40, 52, 64, and 74 ]
  5. Change in serum 1,25-dihydroxyvitamin D (1,25(OH)2D) over time [ Time Frame: Weeks 0, 1, 2, 4, 8, 12, 16, 24, 32, 40, 52, 64, and 74 ]
  6. Change in alkaline phosphatase (ALP) over time [ Time Frame: Weeks 0, 1, 2, 4, 8, 12, 16, 24, 32, 40, 52, 64, and 74 ]
  7. Change in urinary phosphorus over time [ Time Frame: Weeks 0, 1, 2, 4, 8, 12, 16, 24, 32, 40, 52, 64, and 74 ]
  8. Change in ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR; algorithm method) over time [ Time Frame: Weeks 0, 1, 2, 4, 8, 12, 16, 24, 32, 40, 52, 64, and 74 ]
  9. Change in recumbent length/standing height in cm, height for age z scores [ Time Frame: Weeks 0, 24, 40 and 64 ]
  10. Change in growth velocity from pre-treatment and post-treatment over time [ Time Frame: Weeks 0, 24, 40 and 64 ]
  11. Change in growth velocity z scores from pre-treatment and post-treatment over time [ Time Frame: Weeks 0, 24, 40 and 64 ]
  12. Six-minute walking test (6MWT) results to examine walking ability (total distance; patients ≥5 years at the time of signing the ICF only) [ Time Frame: Weeks 0, 24, 40 and 64 ]
  13. Six-minute walking test (6MWT) results to examine walking ability (percent of predicted normal; patients ≥5 years at the time of signing the ICF only) [ Time Frame: Weeks 0, 24, 40 and 64 ]
  14. Ten-item Short Form Health Survey for Children (SF-10) physical domain scores to examine health-related Quality of Life [ Time Frame: Weeks 0, 24, 40 and 64 ]
    The SF-10 is a brief, 10-item, guardian-completed assessment designed to measure the physical and psychosocial functioning of children. The physical functioning (PHS) domain includes 5 questions that assess limitations in physical activities because of health problems. The PHS domain score was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.

  15. Ten-item Short Form Health Survey for Children (SF-10) Psychosocial scores to examine health-related Quality of Life [ Time Frame: Weeks 0, 24, 40 and 64 ]
    The SF-10 is a brief, 10-item, guardian-completed assessment designed to measure the physical and psychosocial functioning of children. The Psychosocial functioning (PSS) domain includes 5 questions that assess limitations in psychosocial activities because of health problems. The PHS domain score was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.

  16. Face Pain Scale-Revised (FPS-R) scores to examine health-related Quality of Life [ Time Frame: Weeks 0, 24, 40 and 64 ]
    The FPS-R is a dimensionless 10 point Likert scale used to assess self-reported pain intensity on a scale from 0 (no pain) to 10 (most pain you can imagine). Greater pain scores are indicative of more severe pain.

  17. Patient-Reported Outcomes Measurement Information System (PROMIS) scores to examine health-related Quality of Life [ Time Frame: Weeks 0, 24, 40 and 64 ]
    The PROMIS was developed by the National Institutes of Health and uses domain-specific measures to assess patient well-being (Broderick et al. 2013), (NIH 2015). It uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. For the Pain Interference Domain, decreases indicate less pain, for the Physical Function Mobility Domain, increases indicate greater mobility and for the Fatigue Domain, decreases indicate less fatigue.


Other Outcome Measures:
  1. Safety of KRN23 by studying the number, severity and relatedness of Adverse Events (including laboratory and imaging assessments) [ Time Frame: Week 0 to Week 76 ]
    Incidence, frequency, and severity of AEs and SAEs, including clinically significant changes in laboratory assessments as well as ECHO, ECG, ultrasound, vital sign, X-Ray images and Anti-KRN23 antibody.

  2. Pharmacokinetics (PK): KRN23 concentrations [ Time Frame: Weeks 0, 1, 2, 4, 8, 16, 24, 40, 64, and 74 ]
  3. Change from Week -14 to Baseline in serum phosphorus over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  4. Change from Week -14 to Baseline in serum 1,25(OH)2D over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  5. Change from Week -14 to Baseline in plasma iPTH over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  6. Change from Week -14 to Baseline in serum calcium over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  7. Change from Week -14 to Baseline in urinary phosphorus over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  8. Change from Week -14 to Baseline in TmP/GFR (algorithm method) over time during Run-in Period [ Time Frame: Week -14, -10 and -4 ]
  9. Safety of conventional therapy by studying the number, severity and relatedness of Adverse Events [ Time Frame: Week -14 to Week 0 ]
    Incidence, frequency, and severity of AEs and SAEs, including clinically significant changes in laboratory assessments during Run-in period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female Chinese patients, aged 1 to ≤12 years at ICF signature with radiographic evidence of rickets
  2. Diagnosis of XLH supported by either of the following:

    • Confirmed PHEX mutation (prior to the study with historic record) in the patient or a directly related family member with approximate X linked inheritance
    • Serum intact FGF23 level ≥30 pg/mL by Kainos assay at Screening
  3. Able to receive conventional therapy (oral phosphate and pharmacologic vitamin D)
  4. Biochemical findings associated with XLH: Serum phosphorus <3.0 mg/dL (0.97 mmol/L). Serum phosphorus may be re tested (once only) at least 7 days after discontinuation of therapy, if applicable ([see Section 3.1])
  5. Serum creatinine within age-adjusted normal range (based on overnight fasting [minimum 4 hours] values collected at Screening)
  6. Serum 25(OH)D above or equal to the lower limit of normal (≥16 ng/mL) at Screening. If 25(OH)D levels are below the normal range, 25(OH)D supplementation will be prescribed. Assuming a patient meets all other eligibility requirements, the patient may be re tested for serum 25(OH)D after a minimum of 7 days of treatment
  7. Willing to provide access to prior medical records for the collection of historical growth and radiographic data and disease history
  8. Written or verbal assent (as appropriate for the patient and region) by the patient and written informed consent by legally authorized representatives provided after the nature of the study has been explained, and prior to any research-related procedures
  9. Be willing and able to complete all aspects of the study, adhere to the study visit schedule and comply with the assessments, as judged by the investigator or subinvestigator
  10. Female patients who have reached menarche must have a negative pregnancy test at Screening and be willing to have additional pregnancy testing during the study. If sexually active, male and female patients must be willing to use an effective method of contraception for the duration of the study and for 12 weeks after the last dose of IP

Exclusion Criteria:

  1. Positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibody at Screening
  2. Tanner stage 4 or higher through physical examination
  3. Height percentile >50% based on country specific norms
  4. Use of a pharmacologic vitamin D, its metabolites, or analogs, oral phosphate for treatment of XLH, aluminum hydroxide antacids, acetazolamide, thiazide diuretics, and/or systemic corticosteroids within 7 days prior to Week -14
  5. Current or prior use of leuprorelin, triptorelin, goserelin, or other drugs known to delay puberty
  6. Use of growth hormone therapy within 12 months before ICF signature
  7. Have uncontrolled diabetes mellitus, defined as glycated hemoglobin (HbA1c) >8.5% at Screening
  8. Presence of nephrocalcinosis on renal ultrasound Grade 4 based on the following scale:
  9. Planned or recommended orthopedic surgery (implantation or removal), including staples, 8 plates, or osteotomy, within the first 40 weeks of the study
  10. Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the age adjusted normal limits (based on overnight fasting [minimum 4 hours] values collected at the Screening)
  11. Evidence of hyperparathyroidism (parathyroid hormone [PTH] levels 2.5 × ULN)
  12. Use of medication to suppress PTH (e.g., Sensipar®, cinacalcet, calcimimetics) within 2 months prior to ICF signature
  13. Presence or history of any condition that, in the view of the investigator or subinvestigator, places the subject at high risk of poor treatment compliance or of not completing the study
  14. Presence of a concurrent disease or condition that would interfere with study participation or affect safety
  15. History of recurrent infection or predisposition to infection, or of known immunodeficiency
  16. Use of therapeutic mAb within 90 days prior to ICF signature or history of allergic or anaphylactic reactions to any mAb
  17. Presence or history of any hypersensitivity to KRN23 excipients that, in the judgment of the investigator or subinvestigator, places the patient at increased risk for adverse effects
  18. Use of any investigational product or investigational medical device within 30 days prior to ICF signature, or need for the use of any investigational agent prior to completion of all scheduled study assessments
  19. Other patients who are considered to be ineligible for the study by the investigator or subinvestigator for reasons other than the above

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04842032


Locations
Layout table for location information
China
Peking Union Medical College Hospital
Beijing, China
Guangzhou Women and Children Medical Center
Guangzhou, China
Shanghai 6th Hospital
Shanghai, China
Shanghai Xinhua Hopsital
Shanghai, China
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
Sponsors and Collaborators
Kyowa Kirin Co., Ltd.
Layout table for additonal information
Responsible Party: Kyowa Kirin Co., Ltd.
ClinicalTrials.gov Identifier: NCT04842032    
Other Study ID Numbers: KRN23-CN006
CTR20210505 ( Other Identifier: www.chinadrugtrials.org.cn )
First Posted: April 12, 2021    Key Record Dates
Last Update Posted: April 11, 2023
Last Verified: April 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Familial Hypophosphatemic Rickets
Hypophosphatemia
Phosphorus Metabolism Disorders
Metabolic Diseases
Rickets, Hypophosphatemic
Rickets
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Hypophosphatemia, Familial
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Urologic Diseases
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Male Urogenital Diseases
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Calcium Metabolism Disorders
Vitamin D Deficiency
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders